4D Molecular Therapeutics (FDMT) CFO reports no securities holdings

Rhea-AI Filing Summary

4D Molecular Therapeutics, Inc. reported that its Chief Financial Officer, Kristian Humer, had no beneficial ownership of the company’s securities as of December 9, 2025. The Section 16(a) insider ownership report indicates that no non-derivative or derivative securities of 4D Molecular Therapeutics are beneficially owned, and the filing was made for one reporting person.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Humer Kristian

(Last) (First) (Middle)

C/O 4D MOLECULAR THERAPEUTICS, INC.

5858 HORTON STREET #455

(Street)

EMERYVILLE CA 94608

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/09/2025

3. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Scott Bizily as Attorney-in-Fact for Kristian Humer	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider information did 4D Molecular Therapeutics (FDMT) disclose in this filing?

The company disclosed that its Chief Financial Officer, Kristian Humer, reported no beneficial ownership of 4D Molecular Therapeutics, Inc. securities as of December 9, 2025.

Which executive is covered by this 4D Molecular Therapeutics (FDMT) insider ownership report?

The report covers Kristian Humer, who is identified as an officer of 4D Molecular Therapeutics, Inc. with the title Chief Financial Officer.

Does the 4D Molecular Therapeutics (FDMT) CFO hold any company shares or derivative securities?

No. The explanation of responses states that no securities are beneficially owned, meaning no non-derivative or derivative securities of the company are reported as owned.

What is the event date referenced in this 4D Molecular Therapeutics (FDMT) insider filing?

The date of the event requiring the statement is listed as December 9, 2025.

Who signed this 4D Molecular Therapeutics (FDMT) beneficial ownership report?

The report is signed “/s/ Scott Bizily as Attorney-in-Fact for Kristian Humer”, indicating it was filed on behalf of the Chief Financial Officer.